New York, NY — October 29, 2013
Anavex Life Sciences Corp. (OTCQB: AVXL) today announced that Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM, will be presenting new data supporting the investigational compound ANAVEX 2-73 as a potential therapeutic for the treatment of Alzheimer’s disease. The data will be presented in a poster presentation, co-authored by Valentine Lahmy, PharmD and Vanessa Villard, PhD, Amylgen, at the Society for Neuroscience 2013 Annual Meeting, which takes place November 9-13, 2013 in San Diego, California. Anavex is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates for the treatment of Alzheimer’s disease and other neurodegenerative disorders, as well as oncology therapeutics.
The findings will be presented during the following poster session:
Title: Chronic treatment with the tetrahydrofuran derivative ANAVEX 2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer’s disease model
Date: Saturday, November 9, 2013
Time: 4:00 PM – 5:00 PM PDT
Place: San Diego Convention Center, Halls B-H
111 W. Harbor Drive, San Diego, CA 92101
ANAVEX 2-73 is an orally available small molecule being investigated for the treatment of Alzheimer’s disease. In addition to pre-clinical data indicating that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer’s disease, there was also a highly encouraging synergistic effect observed between ANAVEX 2-73 and Aricept® (donepezil). The combined therapeutics produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer. ANAVEX 2-73, a drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information Anavex Life Sciences Corp. Research & Business Development Email: email@example.com